In a report released today, Shane Storey from Wilsons maintained a Buy rating on B2Gold, with a price target of C$9.25. The company’s shares closed yesterday at $5.33.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Storey covers the Healthcare sector, focusing on stocks such as Immutep Ltd, Telix Pharmaceuticals, and Clinuvel Pharmaceuticals . According to TipRanks, Storey has an average return of 9.3% and a 54.35% success rate on recommended stocks.
In addition to Wilsons, B2Gold also received a Buy from BMO Capital’s Brian Quast in a report issued today. However, on September 29, RBC Capital maintained a Hold rating on B2Gold (NYSE MKT: BTG).
BTG market cap is currently $7.03B and has a P/E ratio of -16.05.
Based on the recent corporate insider activity of 104 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BTG in relation to earlier this year.
Read More on BTG:
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)